Skip to content

Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester

Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02990767
Enrollment
1000
Registered
2016-12-13
Start date
2016-06-30
Completion date
2019-06-30
Last updated
2016-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Eclampsia

Brief summary

The aims of this study are to develop algorithms based on a combination of maternal factors, uterine artery PI, MAP and serum biomarkers to estimate patient-specific risks for early Preeclampsia (PE) and to evaluate the screening performance of such algorithms in twins.

Detailed description

Preeclampsia (PE) is still a leading cause of fetal and maternal morbidity and mortality with an incidence of 3-5% worldwide. Despite intensive research efforts the pathogenesis of the disease is still unknown but it is likely to be multifactorial.Clinical risk factors traditionally have been used to identify women at high risk of developing preeclampsia,and biophysical factors that may help predict hypertensive disorders of pregnancy.In addition,changes in the serum concentrations of angiogenic and antiangiogenic factors are implied in the pathogenesis of PE and have possible relevance in the diagnosis of the disease.

Interventions

None listed

Sponsors

Shanghai First Maternity and Infant Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* twins pregnancies delivering a phenotypically normal stillbirth or live birth at or after 24 weeks of gestation. * twins pregnancies at at 11-14 weeks of gestation

Exclusion criteria

* pregnancies with major fetal abnormalities and those ending in termination, miscarriage or fetal death before 24 weeks

Design outcomes

Primary

MeasureTime frame
Early preeclampsia1 year

Secondary

MeasureTime frame
Selective intrauterine fetal growth restriction1 year

Countries

China

Contacts

Primary ContactLuming Sun, PhD
luming_sun@163.com021-20261151

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026